Valuation: Evogene Ltd.

Market Cap 6.04M 0 5.17M 4.84M 4.43M 8.31M 578M 8.42M 57.17M 22.29M 290M 22.67M 22.18M 960M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.04M 0 5.17M 4.84M 4.43M 8.31M 578M 8.42M 57.17M 22.29M 290M 22.67M 22.18M 960M EV / Sales 2026 *
4.07x
EV / Sales 2027 * 2.32x
Free-Float
72.15%
Yield 2026 *
-
Yield 2027 * -
1 day-3.45%
1 week-9.27%
Current month+11.45%
1 month+2.06%
3 months-17.00%
6 months-36.82%
Current year-42.35%
1 week 165.1
Extreme 165.1
191
1 month 143.6
Extreme 143.6
229.8
Current year 115.1
Extreme 115.1
410
1 year 115.1
Extreme 115.1
478.7
3 years 115.1
Extreme 115.1
3,700
5 years 115.1
Extreme 115.1
10,430
10 years 115.1
Extreme 115.1
33,500
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2004
Corporate Officer/Principal - -
Corporate Officer/Principal - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member 77 03/06/2010
Chairman 60 01/06/2021
Date Insider Type Main position Quantity % Market Cap.
11/8/26 Buy

Director

460,000 2.9111%
4/8/26 Buy

Director

800,000 5.0628%
18/3/26 Other

Executive/Senior Manager

40,000 0.4588%
Change 5-day change 1-year change 3-year change Capi.($)
-3.45%-9.27%-58.69%-94.09% 6.04M
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.06%+3.06%+67.35%+101.83% 27.65B
Weighted average by Cap. +0.49%+4.72%+99.57%+146.29%

Financials

2026 *2027 *
Net sales 1.48M 0 1.27M 1.19M 1.09M 2.04M 142M 2.07M 14.05M 5.48M 71.33M 5.57M 5.45M 236M 2.6M 0 2.23M 2.08M 1.91M 3.58M 249M 3.63M 24.62M 9.6M 125M 9.76M 9.55M 413M
Net income -16.69M -0 -14.29M -13.37M -12.24M -22.98M -1.6B -23.28M -158M -61.62M -802M -62.66M -61.29M -2.65B -13.92M -0 -11.92M -11.15M -10.21M -19.16M -1.33B -19.41M -132M -51.39M -669M -52.25M -51.11M -2.21B
Net Debt - -
Logo Evogene Ltd.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Employees
52
Date Price Change Volume
21/08/26 ILA 173.30 -3.45% 32,101
20/08/26 ILA 179.50 +4.06% 62,975
19/08/26 ILA 172.50 +1.59% 39,678
18/08/26 ILA 169.80 -5.14% 72,446
17/08/26 ILA 179.00 -6.28% 132,191

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVGN Stock